Effect of Helicobacter pylori infection on outcomes in resected gastric and gastroesophageal junction cancer

Abstract

Background:Helicobacter pylori (H pylori) infection is a known risk factor for gastric cancer (GC) and has been linked with gastroesophageal junction (GEJ) cancer. Studies examining the relationship between H.pylori infection, GC characteristics and prognosis are limited and have yielded conflicting results. We report on the clinicopathologic characteristics and oncologic outcomes of gastric and GEJ cancer patients with and without a history of H. pylori treated at our institution. Results: Ninety-five patients were identified. The majority of patients were male (61%), white (36%) or Asian (34%), with median age at diagnosis 64. Tumors were stage I (51%), stage II (23%), stage III (25%), and stage IV (1%). H pylori infection status was documented at the time of cancer diagnosis in 89 (94%) patients, and following cancer diagnosis and treatment in 6 (6%) patients. Younger age at diagnosis, Asian race and Lauren histologic classification were associated with H Pylori infection. H pylori positive patients exhibited higher 5-year OS and 5-year RFS compared to H pylori negative patients, though the difference was not statistically significant in either univariate or multivariate analyses. Conclusions:In this retrospective series of predominantly early stage GC and GEJ cancers, H. pylori positive patients were significantly younger at cancer diagnosis and were more frequently Asian compared to H. pylori negative patients. Other demographic and histologic classifications except for Lauren histologic classification were similar between the two groups. H pylori positive patients appeared to have improved outcomes compared to H. pylori negative patients.

Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis

“…Our results suggest that patients positive for H. pylori are prone to have less tumor length (≤4.5 cm) and early-stage (T1) disease, although without statistical significance for the difference (Table 1 ). This trend has also been observed in other studies [ 77 ]. When conducting an analysis stratified by these factors, the association showed a tendency to be more prominent in less tumor length (≤4.5 cm) and less advanced T1-T2 stage (Fig.…”

Activation of CD3+ T cells by Helicobacter pylori DNA vaccines in potential immunotherapy of gastric carcinoma

“…14,15 Some retrospective studies confirm the role of the positive H. pylori status as a beneficial predicative factor, but several reports do not. [11][12][13]16,25,[30][31][32][33][34][35] As shown by the meta-analysis of 12 studies including 2454 patients, the pooled hazard ratio is 0.71 (95%CI: 0.57-0.87; P = 0.001) for OS in patients with Hp-GC compared to those with nHp-GC, thereby suggesting a protective role for H. pylori infection in the prognosis of GC. 27 In addition, patients with Hp-GC in the advanced stages show better response to chemotherapy besides longer median OS compared to those with nHp-GC.…”

Polyphenols as Promising Drugs against Main Breast Cancer Signatures

“…Chronic inflammation has been linked to the development of some tumors [ 162 , 163 , 164 ], and it is known that diseases such as pancreatitis [ 165 ], hepatic steatosis or Crohn’s disease [ 166 ], which present chronic inflammation, significantly increase the risk of cancer. This direct relationship with cancer development is also observed in infectious diseases that produce inflammation, such as hepatitis [ 167 , 168 ] or stomach infection by Helicobacter pylori [ 169 , 170 , 171 ].…”